| Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment (NCT07206264) | Tianjin Medical University Cancer Institute and Hospital | 2025-10-01 |
| FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma (NCT07012798) | Tianjin Medical University Cancer Institute and Hospital | 2025-09-25 |
| Romiplostim N01 in the Treatment of Thrombocytopenia Caused by Cytotoxic Drugs in Breast Cancer Patients (NCT07162519) | Tianjin Medical University Cancer Institute and Hospital | 2025-09-20 |
| Analysis of Deoxyribonucleic Acid and Ribonucleic Acid Next-Generation Sequencing in Non-Small Cell Lung Cancer Patients Without Pathological Complete Response Following Neoadjuvant Immunotherapy (NCT07179445) | Tianjin Medical University Cancer Institute and Hospital | 2025-09-20 |
| Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma (NCT07157306) | Tianjin Medical University Cancer Institute and Hospital | 2025-09-10 |
| A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study) (NCT07119931) | Tianjin Medical University Cancer Institute and Hospital | 2025-09-10 |
| Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC (NCT07038629) | Tianjin Medical University Cancer Institute and Hospital | 2025-09-08 |
| Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer (NCT07153965) | Tianjin Medical University Cancer Institute and Hospital | 2025-09-01 |
| An Exploratory Study on the Efficacy and Safety of Enlonstobart Combined With Concurrent Radiotherapy and Chemotherapy Following Induction Therapy With Enlonstobart Plus Chemotherapy in Patients With Locally Advanced Cervical Cancer. (NCT07776821) | Tianjin Medical University Cancer Institute and Hospital | 2025-09-01 |
| Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma (NCT07099274) | Tianjin Medical University Cancer Institute and Hospital | 2025-08-22 |
| The Possible Range of No.4sb Lymph Node Dissection of Locally Advanced Distal Gastric Cancer (NCT07183150) | Tianjin Medical University Cancer Institute and Hospital | 2025-08-18 |
| Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer (NCT07139470) | Tianjin Medical University Cancer Institute and Hospital | 2025-08-15 |
| RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma (NCT07114432) | Tianjin Medical University Cancer Institute and Hospital | 2025-08-01 |
| Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment (NCT07078305) | Tianjin Medical University Cancer Institute and Hospital | 2025-08-01 |
| The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcinoma: a Single Center, Real-world Study (NCT07078292) | Tianjin Medical University Cancer Institute and Hospital | 2025-08-01 |
| Impact of an Artificial Intelligence-Based Management Model on Psychological and Behavioral Outcomes in Breast Cancer Patients Undergoing Home CDK4/6 Inhibitor Therapy (NCT07409298) | Tianjin Medical University Cancer Institute and Hospital | 2025-07-05 |
| Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors (NCT07058948) | Tianjin Medical University Cancer Institute and Hospital | 2025-07-01 |
| Evaluation of the Efficacy and Safety of Adebrelimab Combined With SOX as Adjuvant Therapy for IIIB and IIIC Gastric Cancer (NCT07033143) | Tianjin Medical University Cancer Institute and Hospital | 2025-07-01 |
| Supermicrosurgical Lymphaticovenous Anastomosis for Prevention of Upper Limb Lymphedema (NCT07026292) | Tianjin Medical University Cancer Institute and Hospital | 2025-07-01 |
| A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL (NCT07031700) | Tianjin Medical University Cancer Institute and Hospital | 2025-07-01 |
| BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma (NCT07008053) | Tianjin Medical University Cancer Institute and Hospital | 2025-07-01 |
| A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer (NCT07035353) | Tianjin Medical University Cancer Institute and Hospital | 2025-06-30 |
| Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer (NCT07005583) | Tianjin Medical University Cancer Institute and Hospital | 2025-06-30 |
| Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure (NCT07708194) | Tianjin Medical University Cancer Institute and Hospital | 2025-06-23 |
| Real-world Studies of CDK4/6 Inhibitors (NCT07407439) | Tianjin Medical University Cancer Institute and Hospital | 2025-06-01 |
| SK-NK Injection in Patients With Advanced Solid Tumors Accompanied by Malignant Ascites (NCT06991478) | Tianjin Medical University Cancer Institute and Hospital | 2025-05-30 |
| Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies (NCT06993025) | Tianjin Medical University Cancer Institute and Hospital | 2025-05-25 |
| A Multicenter Randomized Controlled Clinical Trial of the Impact of Minimally Invasive Abdominal Surgery Esophageal Pressure Monitoring Guided Individualized PEEP on Postoperative Pulmonary Complications in Obese Patients (NCT06996288) | Tianjin Medical University Cancer Institute and Hospital | 2025-05-20 |
| QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer (NCT06917092) | Tianjin Medical University Cancer Institute and Hospital | 2025-05-01 |
| AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer (NCT06938503) | Tianjin Medical University Cancer Institute and Hospital | 2025-04-21 |
| Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy (NCT06914050) | Tianjin Medical University Cancer Institute and Hospital | 2025-04-01 |
| Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC (NCT06939127) | Tianjin Medical University Cancer Institute and Hospital | 2025-04-01 |
| A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies (NCT06914037) | Tianjin Medical University Cancer Institute and Hospital | 2025-03-31 |
| A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer (NCT06944106) | Tianjin Medical University Cancer Institute and Hospital | 2025-03-28 |
| A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid Tumor (NCT06954558) | Tianjin Medical University Cancer Institute and Hospital | 2025-03-18 |
| QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer (NCT06951997) | Tianjin Medical University Cancer Institute and Hospital | 2025-03-07 |
| Observation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal Spray on Optimizing Awake Sedation During Breast-Conserving Surgery for Breast Cancer and Postoperative Awake Status (NCT07350928) | Tianjin Medical University Cancer Institute and Hospital | 2025-03-01 |
| Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma (NCT06867432) | Tianjin Medical University Cancer Institute and Hospital | 2025-03-01 |
| Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer (NCT06814158) | Tianjin Medical University Cancer Institute and Hospital | 2025-03-01 |
| Efficacy of the RayerKnife X Stereotactic Radiotherapy System in the Treatment of Brain Metastases (NCT06852001) | Tianjin Medical University Cancer Institute and Hospital | 2025-03-01 |
| Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC (NCT06890182) | Tianjin Medical University Cancer Institute and Hospital | 2025-03-01 |
| Second-line Immunotherapy for ES-SCLC (NCT06853678) | Tianjin Medical University Cancer Institute and Hospital | 2025-02-28 |
| Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL (NCT06570447) | Tianjin Medical University Cancer Institute and Hospital | 2025-02-27 |
| The Importance of Thymus Anatomy to the Radical Resection of Thyroid Cancer Surgery and the Protection of Parathyroid Function (NCT06851260) | Tianjin Medical University Cancer Institute and Hospital | 2025-02-20 |
| Laparoscopic Staging for Stage III Gastric Cancer (NCT07533825) | Tianjin Medical University Cancer Institute and Hospital | 2025-02-01 |
| A Study of 3D Visualization Techniques to Improve the Quality and Safety of Robot-assisted Nephron Sparing Surgery for Complex Renal Tumors. (NCT06717009) | Tianjin Medical University Cancer Institute and Hospital | 2025-01-01 |
| Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer (NCT06766643) | Tianjin Medical University Cancer Institute and Hospital | 2025-01-01 |
| A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer (NCT06760364) | Tianjin Medical University Cancer Institute and Hospital | 2024-12-25 |
| Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma (NCT06704555) | Tianjin Medical University Cancer Institute and Hospital | 2024-12-20 |
| A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer (NCT06878625) | Tianjin Medical University Cancer Institute and Hospital | 2024-12-06 |
| Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer (NCT07092696) | Tianjin Medical University Cancer Institute and Hospital | 2024-12-01 |
| Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer Patients (NCT06697990) | Tianjin Medical University Cancer Institute and Hospital | 2024-12-01 |
| Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer (NCT06704620) | Tianjin Medical University Cancer Institute and Hospital | 2024-12-01 |
| Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors (NCT06727617) | Tianjin Medical University Cancer Institute and Hospital | 2024-11-19 |
| AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients (NCT06489197) | Tianjin Medical University Cancer Institute and Hospital | 2024-11-16 |
| Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer (NCT06717464) | Tianjin Medical University Cancer Institute and Hospital | 2024-11-12 |
| Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma (NCT06721286) | Tianjin Medical University Cancer Institute and Hospital | 2024-11-12 |
| Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract Carcinoma (NCT06656559) | Tianjin Medical University Cancer Institute and Hospital | 2024-10-01 |
| Spatial Fragmentation Combined With Low-dose Radiotherapy for Immunotherapy Combined With Chemotherapy-resistant Locally Advanced or Advanced Non-small Cell Lung Cancer (NCT06775678) | Tianjin Medical University Cancer Institute and Hospital | 2024-10-01 |
| Validate the Safety and Feasibility of the CT-guided Interventional Robot in Percutaneous Lung Cryablation Procedures (NCT06581107) | Tianjin Medical University Cancer Institute and Hospital | 2024-09-15 |
| Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer (NCT06852287) | Tianjin Medical University Cancer Institute and Hospital | 2024-09-01 |
| Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression (NCT06560528) | Tianjin Medical University Cancer Institute and Hospital | 2024-09-01 |
| A Study of the Effect of Real-time Pressure Controllers on Subjective and Objective Symptoms of Peripheral Neuropathy Induced by Albumin Paclitaxel (NCT07019233) | Tianjin Medical University Cancer Institute and Hospital | 2024-09-01 |
| Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study (NCT07047560) | Tianjin Medical University Cancer Institute and Hospital | 2024-09-01 |
| Efficacy and Safety of Dalpiciclib Plus Toremifene in the Treatment of Advanced First-line HR Positive and HER2 Negative Breast Cancer: a Multicenter, Single Arm, Exploratory Phase II Clinical Study (NCT06495515) | Tianjin Medical University Cancer Institute and Hospital | 2024-08-01 |
| Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients (NCT06463691) | Tianjin Medical University Cancer Institute and Hospital | 2024-08-01 |
| Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma (NCT06512467) | Tianjin Medical University Cancer Institute and Hospital | 2024-07-30 |
| Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy (NCT06498154) | Tianjin Medical University Cancer Institute and Hospital | 2024-07-25 |
| Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer (NCT06483386) | Tianjin Medical University Cancer Institute and Hospital | 2024-07-15 |
| Correlation Study of Serum HER 2 Against HER 2-ADC Drug Efficacy in HER 2 Low-expressing Breast Cancer (NCT06492447) | Tianjin Medical University Cancer Institute and Hospital | 2024-07-04 |
| The Effect of Serum Ferritin in irAE (NCT06702566) | Tianjin Medical University Cancer Institute and Hospital | 2024-07-04 |
| AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC (NCT06472037) | Tianjin Medical University Cancer Institute and Hospital | 2024-07-01 |
| Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma (NCT06474481) | Tianjin Medical University Cancer Institute and Hospital | 2024-07-01 |
| A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC) (NCT06506292) | Tianjin Medical University Cancer Institute and Hospital | 2024-07-01 |
| To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer (NCT06352008) | Tianjin Medical University Cancer Institute and Hospital | 2024-07-01 |
| Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC. (NCT06452602) | Tianjin Medical University Cancer Institute and Hospital | 2024-06-19 |
| Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer (NCT06454448) | Tianjin Medical University Cancer Institute and Hospital | 2024-06-15 |
| CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma (NCT06433362) | Tianjin Medical University Cancer Institute and Hospital | 2024-06-01 |
| Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy (NCT05856864) | Tianjin Medical University Cancer Institute and Hospital | 2024-06-01 |
| Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity Results (NCT06438055) | Tianjin Medical University Cancer Institute and Hospital | 2024-06-01 |
| Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer (NCT06454435) | Tianjin Medical University Cancer Institute and Hospital | 2024-06-01 |
| The Safety and Effectiveness of NEPA in Preventing Postoperative Nausea and Vomiting After General Anesthesia Gastrointestinal Cancer Surgery: A Single-Center Retrospective Study (NCT06417567) | Tianjin Medical University Cancer Institute and Hospital | 2024-05-15 |
| A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC (NCT06375642) | Tianjin Medical University Cancer Institute and Hospital | 2024-05-10 |
| Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (NCT06395870) | Tianjin Medical University Cancer Institute and Hospital | 2024-05-09 |
| A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors (NCT06717022) | Tianjin Medical University Cancer Institute and Hospital | 2024-05-06 |
| Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer (NCT06409429) | Tianjin Medical University Cancer Institute and Hospital | 2024-05-01 |
| Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma (NCT06405061) | Tianjin Medical University Cancer Institute and Hospital | 2024-05-01 |
| A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors (NCT06730659) | Tianjin Medical University Cancer Institute and Hospital | 2024-04-19 |
| Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial (NCT06363734) | Tianjin Medical University Cancer Institute and Hospital | 2024-04-09 |
| Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer (NCT06259058) | Tianjin Medical University Cancer Institute and Hospital | 2024-04-01 |
| Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC (NCT06322563) | Tianjin Medical University Cancer Institute and Hospital | 2024-04-01 |
| Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study (NCT06301399) | Tianjin Medical University Cancer Institute and Hospital | 2024-03-20 |
| Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK) (NCT06221670) | Tianjin Medical University Cancer Institute and Hospital | 2024-03-20 |
| Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）. (NCT06375486) | Tianjin Medical University Cancer Institute and Hospital | 2024-03-14 |
| A Prospective Clinical Study to Validate a Preoperative Risk Scoring Model for LNM in GC Patients (NCT06339307) | Tianjin Medical University Cancer Institute and Hospital | 2024-02-15 |
| A Single-Arm Clinical Trial of Percutaneous Splenic Ablation Combined With Splenic Artery Occlusion for Secondary Hypersplenism. (NCT06292715) | Tianjin Medical University Cancer Institute and Hospital | 2024-01-20 |
| Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer (NCT06282120) | Tianjin Medical University Cancer Institute and Hospital | 2024-01-01 |
| A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors (NCT06143735) | Tianjin Medical University Cancer Institute and Hospital | 2023-12-31 |
| Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients (NCT06383559) | Tianjin Medical University Cancer Institute and Hospital | 2023-12-01 |
| Fruquintinib Combined With TAS102 for Advanced Gastric Cancer (NCT06102785) | Tianjin Medical University Cancer Institute and Hospital | 2023-11-10 |